--Aastrom Biosciences公司4月21日宣布，已达成一项最终协议，收购赛诺菲（Sanofi）细胞治疗和再生医学（CTRM）业务。该笔收购价为650万美元，包括400万美元现金支付和250万美元的票据支付。此次收购预计将在3周内完成。此外，Aastrom还将收购位于美国和丹麦的全球制造和生产中心。
通过收购辉瑞CTRM业务，Aastrom将获得3种自体细胞治疗产品的全球商业化权利。Carticel（自体软骨细胞）是一种自体软骨细胞植入（ACI）产品，于1997年获FDA批准，用于治疗关节软骨缺损，截至目前已开展超过2.2万件植入物。Epicel（培养的自体表皮移植）是一种永久性皮肤替代产品，在美国获批作为一种人道主义使用设备，用于全层烧伤面积≥30%总体表面积的烧伤。MACI（基质诱导的自体软骨细胞植入物）是第三代ACI产品，于1998年在欧盟上市，目前已有超过1万例患者接受治疗。这3种产品在2013年的营收为4400万美元。
对3种旗舰自体细胞治疗组合产品及欧美生产中心的收购，将奠定Aastrom在再生医学领域中的全球领导者地位。
赛诺菲于2011年收购健赞（Genzyme）获得了CTRM业务。
英文原文：Aastrom Announces Definitive Agreement to Acquire Sanofi's Cell Therapy and Regenerative Medicine Business
Acquisition of Landmark Autologous Cell Therapy Portfolio and Manufacturing Centers in U.S. and Europe Positions Aastrom as a Global Leader in Regenerative Medicine
ANN ARBOR, Mich., April 21, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has entered into a definitive agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine (CTRM) business for a purchase price of $6.5 million, with $4 million payable in cash at closing and $2.5 million payable in the form of a promissory note. The acquisition is subject to customary closing conditions and is scheduled to close in approximately three weeks.
Through the CTRM acquisition, Aastrom is acquiring global commercial rights to three marketed autologous cell therapy products. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant (ACI) currently marketed in the United States for the treatment of articular cartilage defects. Epicel® (cultured epidermal autografts) is a permanent skin replacement for full thickness burns greater than or equal to 30% of total body surface area, and is marketed in countries around the world. MACI® (matrix-induced autologous chondrocyte implant) is a third-generation ACI product currently marketed in the European Union. Revenues of those three products were $44 million in 2013. Aastrom will also acquire global manufacturing and production centers located in the United States and Denmark.
"The acquisition of Sanofi's CTRM business is a transformative transaction that positions Aastrom as a fully-integrated global regenerative medicine company," said Nick Colangelo, president and chief executive officer of Aastrom. "The CTRM business brings us global manufacturing, marketing and sales capabilities that are structured to support the current portfolio of marketed products as well as our future product development plans. This transaction also provides us with a platform to generate operating income to support the development of our high-potential pipeline products and continued growth through additional strategic transactions."
"Sanofi's CTRM business, a pioneering organization with more than 20 years of experience in cell therapy and regenerative medicine, developed and marketed some of the first regenerative medicine products in the world," continued Mr. Colangelo. "We look forward to working with the talented CTRM team to build Aastrom into the leading cell therapy company in the regenerative medicine field."
Sanofi acquired the CTRM business in 2011 through the acquisition of Genzyme Corporation.
Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant (ACI) for the treatment of articular cartilage defects, was approved by the FDA in 1997 and has had more than 22,000 implants performed since that time. MACI® (matrix-induced autologous chondrocyte implant), is a third-generation ACI product commercially available in the European Union since 1998, with more than 10,000 patients treated to date. Epicel® (cultured epidermal autografts), a permanent skin replacement for full thickness burns greater than or equal to 30% of total body surface area, is approved for use as a humanitarian use device in the United States and supplied to patients outside the U.S. on a named-patient basis.
Aastrom Biosciences
Aastrom Biosciences is the leader in developing patient-specific, expanded multicellular therapies for use in the treatment of patients with severe, chronic cardiovascular diseases. The company's proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced ixmyelocel-T into late-stage clinical development, including a Phase 2b clinical trial in patients with ischemic dilated cardiomyopathy.